Amplification of Chlamydia trachomatis DNA by polymerase chain reaction was compared with amplification by ligase chain reaction (LCR). Both amplification procedures were able to consistently amplify amounts of DNA equivalent to three C. trachomatis elementary bodies. All 15 C. trachomatis serovars were amplified to detectable levels by LCR, and no DNA from 16 organisms potentially found in clinical specimens or from Chlamydia psittaci and Chlamydia pneumoniae was amplified by LCR.
Chlamydia trachomatis is an obligate intracellular parasite which has 15 serovars distinguished by variable regions of the major outer membrane protein (MOMP) and contains a 7.5-kb cryptic plasmid which appears to be required for intracellular growth (13, 27) . C. trachomatis is a major human pathogen causing a variety of diseases. There are approximately 4 million cases of C. trachomatis-caused sexually transmitted disease occurring annually in the United States alone (14, 16, 17) . Exposure to C. trachomatis during birth can lead to conjunctivitis and pneumonia in the neonate (1) . C. trachomatis also causes trachoma, the leading cause of preventable blindness worldwide. Over 500 million people are estimated to be infected, with 7 million being blind (6) .
No diagnostic method for C. trachomatis has yet been shown to approach 100% sensitivity (2) . The "gold standard" with which all other methods are compared is cell culture, which detects at best 80% of genital infections and less than 50% of trachoma and the results of which can vary considerably depending on sample handling and culture procedures (12, 21) . Nonculture methods have been developed to lessen the complexity and decrease the time required for chlamydia detection (5, 12, (22) (23) (24) (25) . Recently, polymerase chain reaction (PCR) procedures have been used to amplify chlamydia-specific DNA sequences prior to detection to increase sensitivity (7, 8, 18, 19) .
In this study amplification of C. trachomatis DNA by PCR was compared with amplification by ligase chain reaction (LCR). A detailed description of LCR has been published in a recent review (4 by proteinase K digestion followed by chloroform-phenol extraction and ethanol precipitation (20 of less than 0.5 genome per amplification reaction. This level of detection, however, was not consistently achieved because of the lower probability of pipetting one EB into the reaction mixture. Consistent amplification to detectable levels was seen at the three-EB dilution point.
For the LCR 5 ,ul of sample was also used, but the total reaction volume was 50 ,ul. The reaction mixture contained 8 pul of 5x LCR buffer {250 mM EPPS [N-(2-hydroxyethyl) piperazine-N-(3-propanesulfonic acid)], 50 mM MgCl2, 50 mM NH4Cl, 5 (20) , and film was exposed to the wet gels to detect product.
An autoradiograph of the acrylamide gel of the LCR product using MOMP probe set 1 revealed detection of amplification product from the three-EB dilution panel member (Fig. lb) . As with the PCR amplification, consistent amplification was not observed in dilutions below three EB. Similar results were observed for LCR amplification and detection of product with the other MOMP probe set and the plasmid probe set (data not shown).
The possibility of being able to detect as few as three EB in a clinical sample raises the question of the clinical significance of finding such low numbers in a patient. In one study determining inclusion-forming units (IFU) recovered from 1,231 infected women, 25% had fewer than 100 IFU/ml (3) . In another study of 580 women, 34% had fewer than 100 IFU per monolayer (11) . The With LCR an additional probe was not needed to confer additional specificity as was the case with PCR. Specificity is inherent in the probes in which even a 1-base mismatch near the junction of the probes inhibits ligation (15, 26) .
LCR has proven to be a fast and sensitive amplification procedure. Amplification and detection by LCR were equivalent to those by PCR, and both methods may be able to detect organisms beyond clinically relevant levels. Detection of LCR product lends itself well to nonisotopic procedures through the use of haptens on either end of the probe pairs. When ligated together, the product would serve as a bridge between capture and detector antibodies. Without ligation, no bridge could be formed. This scheme could then be used in any of a variety of automated enzyme-linked immunoassay detection instruments.
